Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Raw Materials (2020 - 2025)

Puma Biotechnology (PBYI) has disclosed Raw Materials for 6 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials fell 55.28% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Dec 2025, down 55.28%, and an annual FY2025 reading of $3.2 million, down 55.28% over the prior year.
  • Raw Materials was $3.2 million for Q4 2025 at Puma Biotechnology, down from $3.6 million in the prior quarter.
  • Across five years, Raw Materials topped out at $7.2 million in Q4 2024 and bottomed at $211000.0 in Q3 2024.
  • Average Raw Materials over 5 years is $3.6 million, with a median of $3.6 million recorded in 2025.
  • The sharpest move saw Raw Materials crashed 83.74% in 2024, then skyrocketed 1626.07% in 2025.
  • Year by year, Raw Materials stood at $4.6 million in 2021, then crashed by 63.25% to $1.7 million in 2022, then surged by 239.07% to $5.7 million in 2023, then rose by 26.17% to $7.2 million in 2024, then crashed by 55.28% to $3.2 million in 2025.
  • Business Quant data shows Raw Materials for PBYI at $3.2 million in Q4 2025, $3.6 million in Q3 2025, and $6.5 million in Q2 2025.